Podcast
Episode 87: Severe Multiple Sclerosis and the CASA-MS Study
Author(s):
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert Zivadinov, MD, PhD. [LISTEN TIME: 30 minutes]
Robert Zivadinov, MD, PhD
Episode 87 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 87, "Severe Multiple Sclerosis and the CASA-MS Study," features an exclusive interview with Robert Zivadinov, MD, PhD, director of the Buffalo Neuroimaging Analysis Center, and a professor of neurology and biomedical informatics at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo. He discussed the recent CASA-MS study that he and colleagues conducted into a subgroup of patients with multiple sclerosis (MS) who develop rapid and progressive disability at a relatively young age, which he presented earlier this year at the 2023 Americas Committee for Treatment and Research in MS Forum,1 and the critical effectively need to treat this group of patients. The study was carried out at The Boston Home, a specialized residential facility for individuals with advanced progressive neurological disorders, in Dorchester, Massachusetts, and at the University at Buffalo, in New York.
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Phase 3 Study of GTX-104 in Subarachnoid Hemorrhage Expected to Proceed Following FDA Feedback
- FDA Places Partial Hold on Evobrutinib Initiation in Newly Enrolled Patients With MS
- FDA Panel Votes in Favor of Brexpiprazole as Potential Therapy for Alzheimer Agitation
- FDA Approves IntelGenx and Gensco's Rizatriptan for Acute Migraine Treatment
- DEA Rules Fenfluramine No Longer a Controlled Substance
- Atogepant’s Indication Expanded to Include Prevention of Chronic Migraine
- FDA Grants Breakthrough Device Designation to Reach Neuro’s Chronic Stroke Platform
- FDA Approves CSL Behring's Immune Globulin Subcutaneous Prefilled Syringe for PI and CIDP
EPISODE BREAKDOWN
- 1:10 – Background on the CASA-MS study subpopulation
- 3:45 – Topline results of the study
- 6:05 – The need for further clarification in MS populations
- 7:10 – The utility of biomarkers such as GFAP
- 12:15 – Further assessment plans for the CASA-MS cohort
- 14:15 – Neurology News Minute
- 18:35 – Access to the tools to characterize progressive MS
- 21:30 – The potential with portable MRI and artificial intelligence
- 25:25 – Unmet needs in progressive MS
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below:
REFERENCE
1. Zivadinov R, Jakimovski D, Burnham A, et al. Comprehensive Assessment of Severely Affected Multiple Sclerosis (CASA-MS) Study. Presented at: ACTRIMS Forum; February 25-28, 2023; San Diego, CA. P430. www.abstractsonline.com/pp8/#!/10822/presentation/468
